References
Thomas D, Ali Z, Zachariah S, et al. Coxibs refocus attention on the cardiovascular risks of non-aspirin NSAIDs. Am J Cardiovasc Drugs (Epub 28 Mar 2017). doi:10.1007/s40256-017-0223-6
Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med. 2016;375(26):2519–29.
Protocol for: Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med. 2016;375(26):2519–29. doi:10.1056/NEJMoa1611593
Supplement to: Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med. 2016;375(26):2519–29. doi:10.1056/NEJMoa1611593
Coxib and traditional NSAID Trialists’ (CNT) Collaboration, Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769–79.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
No sources of funding were used to assist with the preparation of this manuscript.
Conflict of interest
Drs. Urtasun, Prozzi, Marín, Buschiazzo, Cañás, Dorati, and Mordujovich have no potential conflicts of interest that might be relevant to the content of this letter.
Rights and permissions
About this article
Cite this article
Urtasun, M.A., Prozzi, G.R., Marín, G.H. et al. Comment on: “Coxibs Refocus Attention on the Cardiovascular Risks of Non-Aspirin NSAIDs”. Am J Cardiovasc Drugs 17, 493–495 (2017). https://doi.org/10.1007/s40256-017-0235-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40256-017-0235-2